OR
HAE icon

Olympiad Research’s Haemonetics HAE Stock Holding History

Olympiad Research’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,099
Closed -$350K – 409
2024
Q1 		$350K Buy
4,099
+972
+31% +$76.3K 0.23% 154
2023
Q4 		$267K Sell
3,127
-1,515
-33% -$131K 0.21% 193
2023
Q3 		$416K Buy
4,642
+2,255
+94% +$201K 0.41% 50
2023
Q2 		$203K Buy
+2,387
New +$202K 0.2% 218
2020
Q4 		– Sell
-3,250
Closed -$284K – 223
2020
Q3 		$284K Sell
3,250
-3,116
-49% -$272K 0.14% 175
2020
Q2 		$570K Buy
6,366
+2,569
+68% +$259K 0.4% 30
2020
Q1 		$378K Sell
3,797
-120
-3% -$13K 0.38% 61
2019
Q4 		$450K Buy
+3,917
New +$474K 0.35% 34

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Olympiad Research's HAE Position: Q2 2024 in Review

Olympiad Research sold out of Haemonetics (HAE) in Q2 2024, closing a stake of 4,099 shares — an estimated $350K sold.

Olympiad Research first reported a position in HAE in Q4 2019 and held it in 8 quarters. The position peaked at $570K in Q2 2020. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • Olympiad Research reported no remaining Haemonetics position as of Q2 2024 after selling out during the quarter.
  • Olympiad Research sold 4,099 Haemonetics shares in Q2 2024, an estimated $350K.
  • Olympiad Research first reported a position in Haemonetics in Q4 2019 and held it in 8 quarters.
  • Olympiad Research's Haemonetics position peaked at $570K in Q2 2020.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on Olympiad Research's 13F filing for Q2 2024, filed 12 Aug 2024.